menu
    • menu
    [{"orgOrder":0,"company":"Cristalia Produtos Quimicos Farma. Ltda","sponsor":"Formosa Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"TAIWAN","productType":"Steroid","year":"2024","type":"Licensing Agreement","leadProduct":"Clobetasol Propionate","moa":"Glucocorticoid receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Cristalia Produtos Quimicos Farma. Ltda","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Cristalia Produtos Quimicos Farma. Ltda \/ Cristalia Produtos Quimicos Farma. Ltda","highestDevelopmentStatusID":"15","companyTruncated":"Cristalia Produtos Quimicos Farma. Ltda \/ Cristalia Produtos Quimicos Farma. Ltda"},{"orgOrder":0,"company":"Cristalia Produtos Quimicos Farma. Ltda","sponsor":"Kashiv BioSciences","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2025","type":"Licensing Agreement","leadProduct":"Omalizumab","moa":"Ig epsilon chain C region","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"Cristalia Produtos Quimicos Farma. Ltda","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Cristalia Produtos Quimicos Farma. Ltda \/ Cristalia Produtos Quimicos Farma. Ltda","highestDevelopmentStatusID":"10","companyTruncated":"Cristalia Produtos Quimicos Farma. Ltda \/ Cristalia Produtos Quimicos Farma. Ltda"},{"orgOrder":0,"company":"Cristalia Produtos Quimicos Farma. Ltda","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"BRAZIL","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"CRIS100","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I","graph3":"Cristalia Produtos Quimicos Farma. Ltda","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cristalia Produtos Quimicos Farma. Ltda \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Cristalia Produtos Quimicos Farma. Ltda \/ Undisclosed"}]

    Find Clinical Drug Pipeline Developments & Deals by Cristalia Produtos Quimicos Farma. Ltda

    Menu

    Cristalia Produtos Quimicos Farma. Ltda

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    INSPECTIONS & REGISTRATIONS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Cristalia Produtos Quimicos Farma. Ltda

                            Brazil arrow
                            FNCE
                            Not Confirmed

                            Cristalia Produtos Quimicos Farma. Ltda

                            Brazil arrow
                            FNCE
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Omalizumab

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Study Phase : Phase III

                            Recipient : Kashiv BioSciences

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Kashiv and CRISTÁLIA Enter into Licensing and Supply Agreement in Latin America

                            Details : The agreement aims for the commercialization of ADL-018 (Omalizumab), a proposed biosimilar to Xolair, in Latin America (LATAM).

                            Product Name : Undisclosed

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : Undisclosed

                            September 11, 2025

                            Lead Product(s) : Omalizumab

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Highest Development Status : Phase III

                            Recipient : Kashiv BioSciences

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Cristalia Produtos Quimicos Farma. Ltda

                            Brazil arrow
                            FNCE
                            Not Confirmed

                            Cristalia Produtos Quimicos Farma. Ltda

                            Brazil arrow
                            FNCE
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Clobetasol Propionate

                            Therapeutic Area : Neurology

                            Study Phase : Phase III

                            Recipient : Formosa Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Formosa Pharmaceuticals Licenses APP13007 for Inflammation and Pain Post-Ocular Surgery

                            Details : Under the agreement, Cristália gets exclusive Brazilian rights for commercializing APP13007 (clobetasol propionate ophthalmic nanosuspension) for inflammation and pain following ocular surgery.

                            Product Name : Undisclosed

                            Product Type : Steroid

                            Upfront Cash : Undisclosed

                            January 26, 2024

                            Lead Product(s) : Clobetasol Propionate

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase III

                            Recipient : Formosa Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Cristalia Produtos Quimicos Farma. Ltda

                            Brazil arrow
                            FNCE
                            Not Confirmed

                            Cristalia Produtos Quimicos Farma. Ltda

                            Brazil arrow
                            FNCE
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : CRIS100

                            Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Safety of CRIS100 on Treatment Spinal Cord Injury

                            Details : CRIS100 is a drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Spinal Cord Injuries.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            February 22, 2023

                            Lead Product(s) : CRIS100

                            Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth